- For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis.
- There will likely be easier times ahead, which will allow investors to take calls on the company’s stock with far greater confidence, possibly after SRRA’s ongoing Phase 3 trial results.
- It is a good time to buy SRRA, for the stock price still seems to be only partly reflective of the product strength and potential of the company.
For further details see:
Sierra Oncology: Time To Enter For The Big Pie